PALO ALTO, Calif., May 12, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today announced that an interview with Tony (Bizuo) Liu, Chief Financial Officer of Cellular Biomedicine Group, will be broadcast on Wide World of Stocks on Wednesday, May 13, 5:00 p.m. and 6:00 p.m. EDT into more than 50 million homes nationwide over BizTV, BizTV Radio, and YouTOO America Networks.
In the interview, Mr. Liu discusses the positive interim data from the Company's Phase IIb clinical trial for Rejoin™ human adipose-derived mesenchymal progenitor cell (haMPC) regenerative therapy for Knee Osteoarthritis (KOA), and the progress of its Phase I trials of Chimeric Antigen Receptor T-Cell (CAR-T) immuno-oncology for patients with advanced stage cancer. "It was a pleasure to discuss Cellular Biomedicine Group's strategic initiatives that will further validate our vision of becoming an innovative cell-therapy company that delivers value to our shareholders and that will serve urgent unmet medical needs in China," said Mr. Liu.
WWOS' interview with Cellular Biomedicine Group can be seen nationwide on Wednesday, May 13 on BizTv at 5:00pm EDT and on YouTOO America (formally America One Network) at 6:00pm EDT.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 firstname.lastname@example.org Vivian Chen Managing Director Investor Relations, Grayling +1 347 481-3711 email@example.com
Source:Cellular Biomedicine Group Inc.